Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16372250 | 1.00 | P2RX7 (0.43) | P2RX7TAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL19767310 | 0.85 | TYK2 (0.41) | P2RX7TAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL16372435 | 0.85 | ACKR3 (0.42) | P2RX7ACKR3 | |
| SCHEMBL21273819 | 0.85 | ACKR3 (0.42) | P2RX7ACKR3 | |
| SCHEMBL29367888 | 0.85 | ACKR3 (0.42) | P2RX7ACKR3 | |
| SCHEMBL24543387 | 0.85 | ACKR3 (0.42) | P2RX7ACKR3 | |
| SCHEMBL19771728 | 0.85 | ACKR3 (0.42) | P2RX7ACKR3 | |
| SCHEMBL21273811 | 0.85 | ACKR3 (0.42) | P2RX7ACKR3 | |
| SCHEMBL30704818 | 0.85 | ACKR3 (0.42) | P2RX7ACKR3 | |
| SCHEMBL29687045 | 0.85 | ACKR3 (0.42) | P2RX7ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50724-E1 | 4-membered ring carboxamides used as nematicides | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-06 | — | — | US | disclosed |
| EP-3019476-B1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-9867371-B2 | 4-membered ring carboxamides used as nematicides | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157485-A1 | 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES | TUBA3C, DDT, CYCS | P2RX7 666/4885TAS1R3 3195/4885TAS1R1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.